Tremfya affects specific immune system pathways to reduce inflammation. Like other biologic medications, it can cause side effects that vary between individuals. Some reactions are relatively common, while others may require medical attention. Understanding these effects helps patients recognize changes in their health during treatment.
Common side effects associated with Tremfya include:
Upper respiratory infections: Patients may experience symptoms such as a sore throat, cough, or common cold.
Headaches: Some individuals report headaches during treatment.
Injection site reactions: Redness, swelling, discomfort, or irritation may occur where the medication is injected.
Joint pain: Arthralgia, or joint discomfort, has been reported among patients receiving treatment.
Digestive symptoms: Diarrhea, abdominal discomfort, and gastroenteritis may occur in some patients.
Fungal infections: Certain fungal infections, including tinea infections, have been reported.
Tremfya may increase the risk of infections because it influences immune system activity. Patients with existing infections or a history of recurring infections should discuss these concerns with their healthcare professionals before starting treatment.
Serious allergic reactions, including anaphylaxis, are also possible. Symptoms such as difficulty breathing, swelling, or severe allergic reactions require immediate medical attention. Patients should inform their healthcare professionals about unusual symptoms rather than independently changing their medication schedule.
Long term Tremfya treatment requires continued medical supervision to evaluate its effectiveness and identify potential safety concerns. The monitoring process may depend on the condition being treated, medical history, existing health conditions, and individual treatment response.
Important considerations during ongoing treatment include:
Infection monitoring: Patients should report persistent fever, respiratory symptoms, or other signs of infection. Treatment may need to be interrupted if a clinically important infection develops.
Tuberculosis screening: Healthcare professionals should evaluate patients for tuberculosis before treatment. Monitoring for active tuberculosis symptoms is also important during and after therapy.
Liver health: Drug-induced liver injury has been reported. Patients receiving Tremfya for ulcerative colitis or Crohn’s disease require liver enzyme and bilirubin assessments before treatment, for at least the first 16 weeks, and periodically afterward.
Vaccination requirements: Age-appropriate vaccinations should be completed before treatment begins. Live vaccines should be avoided during Tremfya treatment.
Treatment response: Regular appointments help healthcare professionals assess symptom improvement and determine whether the prescribed treatment remains appropriate.
Allergy history: Patients should disclose previous serious allergic reactions to guselkumab or any medication ingredients before beginning therapy.
Patients should also discuss other prescription medications, supplements, and existing medical conditions with their healthcare professionals. These details can help determine appropriate treatment precautions.
The prescribed dosage and administration schedule should be followed carefully. Patients should not independently skip doses, increase medication amounts, or discontinue treatment without medical guidance.
Long term Tremfya treatment involves balancing symptom management with ongoing safety assessments. Understanding potential side effects, recognizing infection symptoms, completing recommended screenings, and attending regular medical appointments are important parts of treatment management. Individual responses can differ, so healthcare professionals should evaluate the benefits and potential risks throughout therapy. Patients who experience unexpected symptoms or changes in their health should discuss them promptly with their treating healthcare professional to determine the appropriate next steps.